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Anaplastic thyroid carcinoma (ATC) although rare is the most deadly form of thyroid cancer. The fatality rate for
ATC is high-pitched, the survival rate at 1 year after diagnosis is b20%. Control of ATC is severely hard and
widespread with unpredictability. We Previous proved that histone gene reviser and epigenetic changes role
significant parts in papillary and anaplastic thyroid cancer tumorigenesis. Herein, the goal of this study was to
investigate the anti-tumor activities of a HDAC inhibitor, HNHA alone and in combination with sorafenib in ATC
cells in vitro and in vivo and to explore its effects on apoptotic cell death pathways. Three ATC cell lines were
exposed to sorafenib in the presence or absence of HNHA, and cell viability was determined by MTT assay. Effects
of combined treatment on cell cycle and intracellular signaling pathways were assessed by flow cytometry and
western blot analysis. The ATC cell lines xenograft model was used to examine the anti-tumor activity in vivo. Our
data showed that HNHA and sorafenib synergistically decreased cell viability in ATC cells, and also significantly
increased apoptotic cell death in these cells, as proved by the cleavage of caspase-3 and DNA fragmentation.
HNHA and sorafenib combination was reduced anti-apoptotic factor in ATC. Thus, combination therapy with
HNHA and sorafenib significantly decreased vessel density, and most significantly reduced tumor volume and
increased survival in ATC xenografts.
These results propose that HNHA in combination with sorafenib has significant anti-cancer activity in preclinical
models, potentially suggesting a new clinical approach for patients of advanced thyroid cancer type.
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A significant event in the tumorigenic transformation of thyroid
follicular cells is the constitutive stimulation of a single signaling
pathway. This pathway, known the RAS-BRAF-ERK pathway, is
triggered by RET/PTC rearrangement [1]. A high prevalence of
BRAF point mutations occurs in papillary thyroid cancers (PTCs;
about 30–70%) and in anaplastic thyroid carcinomas (ATCs; about
10–40%) [2]. In PTCs, BRAFmutations, RET/PTC rearrangements,
and RAS mutations are mostly mutually exclusive [3].
Patients with the most ordinary type of thyroid cancer, PTC, have
low hazard of recurrence and high survival. However, some patients
Table 1. Cell line characteristics, viability after drug treatment of all thyroid carncer cell lines
examined
8505C SNU-80 GSA1
Age at diagnosis 78 59 74
Gender Female Female Female
Primary disease site Thyroid Thyroid Thyroid









- - Fresh tumor




Table 2. IC50 (half maximal inhibitory concentration) determination using a cell proliferation assay
Cell line Hisopathology Animal Cell proliferation IC50 (μM)
HNHA ± Sorafenib HNHA Sorafenib
8505C Thyroid cancer:
anaplastic
Human 3.82 (±0.5)* 17.42 (±0.6) 10.21 (±0.9)
SNU-80 Thyroid cancer:
anaplastic
Human 0.87 (±1.1)* 2.28 (±0.4) 5.14 (±1.1)
GSA1 Thyroid cancer:
anaplastic
Human 8.72 (±0.5)* 20.14 (±0.5) 23.45 (±0.6)
HNHA and sorafenib combination treatment is a lower IC50 than HNHA or sorafenib alone. Each
data point represents the mean of 3 independent MTT assays for IC50 performed in triplicate. SD,
standard deviation.
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not respond to any chemotherapy, typically dying in a few months
[4,5]. Although rare, ATC is the deadliest form of thyroid cancer; its
fatality rate is high, with a 20% survival rate 1 year after diagnosis.
Many studies have shown histone deacetylase (HDAC) inhibitors
to be effective anticancer agents; therefore, the US Food and Drug
Administration (USFDA) has approved the use of such substances
for treating several cancer types [6,7]. Some HDAC inhibitors are
currently in clinical trials as therapeutic agents alone or in
combination with other anticancer drugs [8]. N-hydroxy-7-
(2-naphthylthio) hepatonomide (HNHA) is a novel HDAC inhibitor
that demonstrates significantly higher anticancer activity than other
HDAC inhibitors such as trichostatin A and suberoylanilide
hydroxamic acid [9–11].
The USFDA recently expanded the permitted use of sorafenib in
treating advanced thyroid cancer [12]. Sorafenib is a multi-kinase
inhibitor that obstructs different signaling pathways, including Raf
kinases, vascular endothelial growth factor receptor (VEGFR), and
platelet-derived growth factor receptors (PDGFRs) [13]. Further-
more, sorafenib has also been approved for the therapy of advanced
renal cell carcinoma (RCC) and various other human cancers,
including thyroid cancer [13–16]. The anticancer activity of sorafenib
occurs via the Raf/Mek/Erk pathway, inducing cell apoptosis and
blocking tumorigenesis [17]. Like HDAC inhibitors, sorafenib
suppresses tumorigenesis by translationally restraining the
anti-apoptotic Bcl-2 family member, Mcl-1 [18,19]. Recently,
Stat3 was shown to be a major kinase-independent target of sorafenib
[20,21]. Unfortunately, however, a majority of the patients does not
respond to sorafenib and HDAC inhibitors, and several patients who
initially do respond subsequently become resistant, with the
continuation of tumor progression [22,23]. Consequently, several
researchers have sought to target human cancer with a combination of
sorafenib and chemotherapy [24,25]. Since most patients with ATC
are diagnosed at an advanced stage, there is a desperate need for new
cancer therapies. The present study suggests a new clinical approach
for ATC treatments by combination therapy with an HDAC
inhibitor and sorafenib. The aim of this study was to determine the
antitumor activities of HNHA alone and in combination with
sorafenib in ATC cells.
Materials and Methods
Tissue Specimens
Fresh tumors were obtained from one patient with biochemically
and histologically proven advanced metastatic ATC, who was treated
at the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, Korea. The tumor tissue were
acquired during surgical resection of primary and metastatic ATC sites.
The research protocol was approved by the Institutional Review Board
of the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei
University College of Medicine (IRB Protocol: 3–2016-0076).
Tumor Cell Isolation and Primary Culture
After resection, tumors were kept in normal saline with antifungal
and antibiotic agents. Normal tissue and fat were removed, and the
tissues were rinsed with 1× Hanks' balanced salt solution (HBSS).
Tumor tissue was minced with dissociation medium, which
contained RPMI-1640 medium (Hyclone, South Logan, UT, USA)
supplemented with 20% FBS and 1 mg/mL of type IV collagenase(Sigma-Aldrich, St Louis, MO, USA). Minced and suspended tumor
cells were filtered through sterile 70-μm-pore nylon cell strainers (BD
Falcon, Franklin Lakes, NJ, USA), rinsed with 50 mL 1× HBSS, and
centrifuged at 1400 rpm for 5 min. Cells were resuspended with
RPMI-1640 medium containing 10% fetal bovine serum (FBS;
Hyclone) and 2% penicillin/streptomycin solution (Gibco, Grand
Island, NY, USA). Cell viability was analyzed by the trypan blue dye
exclusion method.
Cell Culture
ATC cell lines 8505C, SNU-80, and GSA1 were obtained from
the European Collection of Cell Cultures (ECACC, Salisbury,
United Kingdom) or the Korea Cell Line Bank (Seoul National
University, Seoul, Korea) or by tumor cell isolation from the current
patient and grown in RPMI-1640 medium with 10% FBS (Table 1).
Authentication was performed by short tandem repeat profiling,
karyotyping, and isoenzyme analysis.
Cell Viability Assay
Cells were seeded in 96-well plates at 5 × 103 cells per well and
incubated overnight to achieve 70% confluency. The indicated drugs
were added to achieve final concentrations of 0–100 μM. Cells were
then incubated for the indicated time points before the determination
of cell viability, using the MTT reagent according to the
manufacturer's protocol, and absorbance was measured at 490 nm.
Data were expressed as percentages of the signal observed in
vehicle-treated cells and shown as the mean ± SD of triplicate
experiments.
Flow Cytometry Analysis of the Cell Cycle
Cells were treated with HNHA and sorafenib alone or in
combination in RPMI-1640 medium containing 10% FBS for 40
h, harvested by trypsinization, and fixed with 70% ethanol. Cells were
Figure 1. Combination of HNHA and sorafenib suppressed ATC cell proliferation more efficiently than either agent alone. Cell viability and
proliferation assay of HNHA and sorafenib combined and HNHA and sorafenib alone in ATC cells (8505C, A and B; SNU-80, C and D;
GSA1, E and F). Points indicate mean % of the value observed in the solvent-treated control. All experiments were repeated at least 3
times. The data represent the mean ± SD. Experiments were repeated at least 3 times with similar results. * P b .05 vs. control,
** P b .01 vs. control, *** P b .005 vs. control.
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iodide and 100 μg/mL RNase I for 30 min at 37°C. Cell cycle
distribution was then analyzed in the FACSCalibur Flow Cytometer
(BD Biosciences, San Jose, CA, USA). The proportions of cells in the
sub-G0/G1, G0/G1, S, and G2/M phases were analyzed by FlowJo v8
software for MacOSX (Tree Star, Ashland, OR, USA). This
experiment was repeated thrice, and the results were averaged.
Evaluation of Apoptotic Cell Death
Cells were fixed with 4% paraformaldehyde solution for 48 h and
then analyzed using a terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) kit (Promega, Madison, WI, USA). The
apoptotic cells (fluorescent green) and total cells were counted byfluorescence microscopy. Images were acquired under a confocal
microscope (LSMMeta 700, Carl Zeiss, Oberkochen, Germany) and
analyzed using the Zeiss LSM Image Browser software, version
4.2.0121.
Immunoblot Analysis
Equal amounts of protein (20 μg) were separated by 8–10%
SDS-PAGE. The antibodies for p53 and p21 were obtained from
Abcam (Cambridge, UK). Apaf-1, CDK 4, CDK 6, cyclin D1, Bcl-2,
p-NF-κB, caspase-3, and β-actin antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies for GRP78,
PERK, p-PERK, eIF2α, p-eIF2α, ATF4, and CHOP were purchased
from Cell Signaling Technology (Danvers, MA, USA).
Figure 2. Combination of HNHA and sorafenib induced cell cycle arrest and endoplasmic reticulum stress in ATC cellsmore potently than either
agent alone. Immunoblot analysis of the indicated cell lines following exposure to theHNHAand sorafenib combination or each agent singly. The
HNHA and sorafenib combination potently induced the expression of cell cycle arrest proteins and reduced the expression of positive regulators
of the cell cycle (A). 8505C, SNU 80, andGSA1were exposed to the indicated inhibitors for 24 h prior to the analysis of the expression of GRP78,
ATF4,CHOP,PERK, p-PERK, eIF2α, andp-eIF2α (markersof endoplasmic reticulumstress) by immunoblot analysis (B). Cellswereexposed to the
indicated inhibitors, harvested, and stained with propidium iodide before analysis by flow cytometry and FlowJo v8 software (C).
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Human ATC cells (2.0 × 107 cells/mouse) were cultured in vitro
and then injected subcutaneously into the upper left flank region of
female BALB/c nude mice. After 7 days, tumor-bearing mice were
grouped randomly (n = 10/group) and treated with 25 mg/kg
HNHA (intraperitoneally) alone, 80 mg/kg sorafenib (orally) alone,
or a combination of 6.5 mg/kg HNHA and 25 mg/kg sorafenib, once
every 2 days for a total of 10~ 12 injections. Tumor size was
measured every other day using calipers. Tumor volume was
estimated using the following formula: L × S/2 (where L is the
longest diameter and S is the shortest diameter). Animals were
maintained under specific pathogen-free conditions. All experiments
were approved by the Animal Experiment Committee of Yonsei
University.
In Vivo Toxicity Study
In vivo toxicity assays were performed using female BALB/c nude
mice. Six-week-old mice were caged for 1 week for acclimatization.
Each group of 10 mice was administered HNHA or sorafenib alone or
the combination of HNHA plus sorafenib in the previous subsection.
The animals were monitored regularly for external signs of toxicity or
lethality. All animals were housed in cages with five mice per cage,
with a 12-h/12-h light:dark cycle and temperature and humidity of
22 °C and 40–60%, respectively. A standard diet of rodent pellets and
tap water (membrane filter-purified and autoclaved) were provided ad
libitum.
Immunohistochemistry
All tissues were fixed in 10% neutral-buffered formalin and
embedded in paraffin wax by standard protocols. Tissue sections(5 μm) were dewaxed, and antigen retrieval was performed in citrate
buffer (pH 6), using an electric pressure cooker set at 120 °C for 5 min.
Sections were incubated for 5 min in 3% hydrogen peroxide to quench
endogenous tissue peroxidase. All tissue sections were counterstained
with hematoxylin, dehydrated, and mounted.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software
(GraphPad Software Inc., La Jolla, CA, USA). Immunohisto-
chemistry results were subjected to ANOVA followed by a Bonferroni
post hoc test. Values are expressed as means ± SD. Pb.05 indicated
statistical significance.
Results
Synergistic Inhibition by HNHA and Sorafenib in 8505C,
SNU-80, and GSA1 Cells
To investigate the anticancer effects of the synergistic
interaction between HNHA and sorafenib in combination, as
well as their individual effects, on ATC, we assayed 8505C,
SNU-80, and GSA1 cell proliferation in the presence and absence
of these compounds by MTT assay (Table 2). HNHA or sorafenib
treatment alone had a lower IC50 in ATC than the combined
treatment. Further characterization of the synergistic effect of
HNHA and sorafenib on ATC cell viability showed that the
combination reduced the viability of ATC cells to a greater extent
than by either agent alone. The combination of HNHA and
sorafenib suppressed cell proliferation better than either agent
used singly (Figure 1,A, C, and E); moreover, this effect was
concentration-dependent (Figure 1,B, D, and F).
Figure 3. Combination of HNHA and sorafenib significantly induced apoptotic death in ATC cells. Immunoblot analyses suggested that
the indicated inhibitors increased the levels of apoptotic proteins and reduced those of anti-apoptotic proteins in ATC cells (A). TUNEL
assay of ATC cells; TUNEL-positive (apoptotic) cells are indicated (×400) (B, 5805C; C, SNU-80; and D, GSA1).
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Endoplasmic ReticulumStress-DependentCell Cycle Arrest in ATC
Immunoblot analyses of protein levels in ATC (8505C, SNU-80,
and GSA1) cell lines indicated that the HNHA and sorafenib
combination induced more marked increases in the levels of p53 and
p21—well-known arrestors of the cell cycle—and decreases in the
levels of cyclins D1, CDK 4, and CDK 6—positive regulators of the
cell cycle—as compared with HNHA or sorafenib alone (Figure 2A).
We also tested whether these compounds induced endoplasmic
reticulum (ER) stress by treating 8505C, SNU-80, and GSA1 cells
with HNHA or sorafenib alone or in combination for 24 h and
analyzing the expression of GRP78, ATF4, CHOP, PERK, p-PERK,
eIF2α, and p-eIF2α by immunoblotting (Figure 2B). The HNHA
and sorafenib combination-treated cells showed the highest increase
in these markers of ER stress. Flow cytometry was performed to
investigate the effects of these compounds on cell cycle progression.
The HNHA and sorafenib combination showed the most significant
induction of G0/G1 phase arrest and increase in the sub-G0/G1
population (P b .05), indicating the induction of cell cycle arrest and
cell death in the ATC cell lines (Figure 2C). Thus, the synergisticeffect of HNHA and sorafenib most potently induced ER stress,
leading to ER stress-dependent apoptosis, cell cycle arrest, and strong
inhibition of ATC and PTC cell viability.
The HNHA and Sorafenib Combination Induced
Caspase-Mediated Apoptosis of ATC Cell Lines
To study the pro-apoptotic signaling pathways activated by
exposure of ATC cells to HNHA and sorafenib, the expression of
pro-apoptotic (Apaf-1) and anti-apoptotic (phosphorylated NF-κB
p65 and Bcl-2) members of the Bcl-2 family, as well as the cleavage of
caspase-3, were analyzed by immunoblot analysis (Figure 3A). The
results showed that the HNHA and sorafenib combination enriched
the “pro” form of caspase-3 and induced the cleavage of pro-caspase-3
more potently than did HNHA or sorafenib alone (Figure 3A). The
TUNEL assay confirmed that the combination induced apoptosis in
ATC cell lines more potently than did either agent alone (Figure 3,
B–D). These data demonstrated that the synergistic effect of HNHA
and sorafenib efficiently induces apoptosis in ATC cells and that it
exerts this effect via caspase cleavage and inhibition of the Bcl-2
pathway.
Figure 4. Combination of HNHA and sorafenib produced antitumor effects in ATC cell xenografts in vivo. Athymic nude mice with
established tumors were treated with the indicated inhibitors. Data represent themean tumor volumes. HNHA and sorafenib combination
therapy induced more potent inhibition of tumor progression than did HNHA or sorafenib alone, resulting in the maximum prolongation of
survival in mice with ATC (8505C, A–D; SNU-80, E–H; and GSA1, I–L) xenografts (n = 10 mice/group) (A, E, and I). “No tumor + HNHA +
sorafenib” indicates HNHA and sorafenib combination-treated mice with no xenograft; no evidence of systemic toxicity or
treatment-related death was found in HNHA and sorafenib combination-treated groups (B, F, and J). The compounds had no significant
effect on mouse body weight (C, G, and K). Weights of the dissected tumors (D, H, and L). Immunoblot analysis of total proteins isolated
from the tumors (M). * P b .05 vs. control, ** P b .01 vs. control, *** P b .005 vs. control.
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Growth and Improved Survival In Vivo
HNHA and sorafenib markedly suppressed 8505C and SNU-80
cell xenograft tumors; however, their combination exhibited a greater
suppression of these tumors (Figure 4, A, E, and I). Mouse survival
was prolonged significantly by both agents, but their combination
yielded better survival rates (Figure 4, B, F, and J). No evidence of
systemic toxicity or treatment-related death was found in any group.
There was no significant effect on the body weight of mice treated
with HNHA and sorafenib (Figure 4, C, G, and K). The
combination-treated group showed significantly smaller tumor
volumes compared to the groups treated with HNHA or sorafenib
alone (Figure 4, D, H, and L). HNHA and sorafenib synergistically
reduced Bcl-2 (anti-apoptotic protein) levels, increased CHOP (ER
stress protein) levels, and cleaved caspase to a greater extent thanHNHA or sorafenib alone. This implies a more efficient induction of
cell cycle arrest and apoptosis due to ER stress in ATC mouse
xenografts by the combination treatment (Figure 4M).
The HNHA and Sorafenib Combination Therapy Suppressed
Tumor Growth by Down-Regulating the Expression of an
Anti-Apoptotic Factor in ATC Xenografts
Anti-apoptotic activity is an important factor in the assessment of
the biological behavior of tumorigenesis. At present, Bcl-2 is the most
useful marker of anti-apoptosis. We detected this marker by
immunohistochemical examination of 8505C, SNU-80, and GSA1
cell xenograft tumors and found that the combination-treated group
showed the strongest decrease in Bcl-2 expression (Figure 5, A–C),
further confirming that HNHA and sorafenib combination therapy
has potent anticancer activity in the ATC xenograft model.
Figure 5. HNHA and sorafenib combination therapy significantly reduced tumor Bcl-2 expression. Immunohistochemical analysis of the
Bcl-2 protein levels in paraffin-embedded tumor tissues from mice with ATC xenografts. Synergistic activity of the HNHA and sorafenib
combination induced more potent inhibition of tumor Bcl-2 expression than HNHA or sorafenib did alone. MetaMorph 4.6 image-analysis
software was used to quantify Bcl-2 immunostaining. * P b .05; ** P b .01; *** P b .005 for the comparison with the control.
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Thyroid cancer is a common endocrine malignancy [26]. Recent
times have witnessed dramatic improvements in the perception of the
molecular pathogenesis of this cancer, best explained by the essential
roles of certain signaling pathways. The key mechanisms are
epigenetic and genetic modifications in these pathways, such as
uncontrolled methylation and mutation of genes [27,28]. A great
number of these molecular modifications provide clues about novel
prognostic and diagnostic therapeutic targets in thyroid cancer,
thereby providing immense chances for further study and progress in
the development of novel treatment strategies for this cancer.
BRAF, a serine/threonine kinase well-known to stimulate MAPK
pathway mutations, has been implicated in melanoma, colon cancer,
and thyroid cancer [3,29,30]. A high prevalence of BRAF point
mutations in PTCs and ATCs has been reported [2]. However, in
thyroid carcinomas, the pathways and molecules connected to the
effect of BRAF suppression in cellular survival are poorly understood.
Notably, patients with PTC have a low risk of recurrence and high
survival, whereas some patients with ATC show considerablemetastasis and respond poorly to chemotherapy [31–33]. Therefore,
combinations of targeted therapies that shrink ATCs are warranted.
HDAC inhibitors have been used against ATC cells [34,35], and
HNHA has been found to be effective at low doses [11]. HDACs are
histone-modifying enzymes that play major roles in the control of
several proteins that are involved in tumorigenesis. Deviant
expression of some HDACs has been demonstrated in diverse
human cancers [36]. High HDAC1 expression has been linked with a
more advanced tumor–node–metastasis stage, greater cancer cell
invasion, and a lower survival rate in human cancers [37].
Accordingly, HDACs are promising drug targets for treating several
human cancers. Some HDAC inhibitors are being investigated for
their effects against solid and hematologic malignancies [38]. HDAC
inhibitors are also being assessed in combination with radiotherapy,
chemotherapy, and molecular targeted agents [8,39]. In an earlier
study, we reported the anticancer activity of HNHA, an
N-hydroxyacrylamide-derived HDAC inhibitor, in ATC and PTC
cell lines [11]. Furthermore, in ATC and PTC tumor xenograft
models, HNHA was demonstrated to be more effective than
152 Combination Chemotherapy in Anaplastic Thyroid Cancer Park et al. Neoplasia Vol. 19, No. 3, 2017established HDAC inhibitors in suppressing tumor growth without
triggering body weight loss [11].
Sorafenib is an established multi-kinase inhibitor with activity
against the Ser/Thr kinase Raf, which plays a crucial role in tumor cell
proliferation and signaling, as well as angiogenesis-related receptor
tyrosine kinases such as VEGFR2 and PDGFR [13,40,41]. Sorafenib
also targets the Raf/Mek/Erk pathway. One study proved that patients
with high levels of p-Erk have a greater survival rate [14,17]. The use of
this multi-kinase inhibitor was recently permitted for the therapy of
advanced thyroid cancer [42]. In the present study, we found that the
combination therapy of HNHA and sorafenib had a lower IC50 in
ATC than that of either agent alone. The mechanisms underlying
these synergistic anticancer effects of both agents on ATC cell
lines included the induction of cell cycle arrest and apoptosis.
Apoptosis was shown by the increased proportion of cells in
sub-G1 and by the stimulation of caspase 3. The combination
therapy also demonstrated a characteristic effect on cell cycle
progression, whereby G1 arrest was evident in the presence of
lower concentrations of HNHA and sorafenib, as compared to the
levels of HNHA or sorafenib that individually produced this
effect. This finding was consistent with those of previous studies
showing that HNHA or sorafenib when used alone are cytotoxic
and induce G1 arrest at lower concentrations [11,14,43].
This study showed synergistic cytotoxic effects of combined HNHA
plus sorafenib therapy on ATC cell lines, both in vitro and in vivo. The
combination therapy induced a more marked rise in the apoptosis of
ATC cells than did HNHA or sorafenib singly. Consistent with this,
the capacity of HDAC inhibitors to induce p21 expression has been
described in a number of cell types and has been shown to occur
through promoter hyperacetylation [44]. The inhibition of p21
expression affects the lethality of HDAC inhibitors and
DNA-damaging agents in various cancer cell types, such as leukemia,
thyroid cancer, and RCC [10,11,45–47]. It has been suggested that
p21 is cleaved by caspase-3 for DNA injury-mediated apoptosis [48].
Sorafenib-mediated transcriptional suppression may cause the down-
regulation of p21. Besides its role as a cyclin-mediated kinase inhibitor,
some investigations propose that p21 might engage in DNA repair by
controlling the interaction between PARP-1 and base excision repair
factors, thereby participating in resistance to chemotherapeutic agents
[49,50]. Therefore, it will be interesting to investigate whether the
sorafenib-mediated down-regulation of p21 causes the synergistic
interaction between HNHA and sorafenib.
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